Literature DB >> 16211437

Gastric carcinoids: a temporal increase with proton pump introduction.

N Hodgson1, L G Koniaris, A S Livingstone, D Franceschi.   

Abstract

BACKGROUND: Recent reports have indicated a rising incidence of gastric carcinoids. This study aimed to evaluate the incidence pattern of gastric carcinoids in two large population-based cancer registries.
METHODS: The Florida Cancer Data System (FCDS), Florida's statewide cancer registry, and the Surveillance, Epidemiology, and End Results (SEER) program were used. The study population was defined as all cases of gastric carcinoid identified in either database from January 1981 to December 2000. Descriptive statistics and age-adjusted incidence rates were calculated.
RESULTS: There were 326 (FCDS) and 594 (SEER) cases of invasive gastric carcinoid during the 20-year study period. The mean age of the patients was 65 years (range, 21-96 years), and the male:female ratio was 1:1. The age-adjusted incidence rate in FCDS increased from 0.04 (per 100,000 age-adjusted to the 2000 U.S. standard population) to 0.18 in the year 2000. The estimated annual percentage change in incidence was 8.17 in FCDS and 9.17 in SEER (p < 0.05). A decrease in gastric cancer was noted during this same period (from 8.64 to 11.14 cases per 100,000 in FCDS and from 11.14 to 8.06 cases per 100,000 in SEER).
CONCLUSIONS: This study documented a statistically significant eight- or ninefold increase in the incidence of gastric carcinoids in two large databases. The temporal increase in incidence correlates with the introduction and widespread use of proton pump inhibitors since the late 1980s. Other explanations include improved detection with wider application of upper endoscopy. Further epidemiologic studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16211437     DOI: 10.1007/s00464-005-0232-4

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  9 in total

Review 1.  Omeprazole.

Authors:  P N Maton
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

2.  Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats.

Authors:  H Larsson; E Carlsson; H Mattsson; L Lundell; F Sundler; G Sundell; B Wallmark; T Watanabe; R Håkanson
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

3.  Overuse of proton pump inhibitors.

Authors:  M Naunton; G M Peterson; M D Bleasel
Journal:  J Clin Pharm Ther       Date:  2000-10       Impact factor: 2.512

4.  Use of anti-secretory medication: a population-based cohort study.

Authors:  A Lassen; J Hallas; O B Schaffalitzky De Muckadell
Journal:  Aliment Pharmacol Ther       Date:  2004-09-01       Impact factor: 8.171

5.  Cloning and characterization of gastrin receptor from ECL carcinoid tumor of Mastomys natalensis.

Authors:  H Nakata; T Matsui; M Ito; T Taniguchi; Y Naribayashi; N Arima; A Nakamura; Y Kinoshita; K Chihara; S Hosoda
Journal:  Biochem Biophys Res Commun       Date:  1992-09-16       Impact factor: 3.575

Review 6.  Carcinoid tumors of the stomach.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Surg Oncol       Date:  2003-08       Impact factor: 3.279

7.  Effect of a gastrin/cholecystokinin B receptor antagonist, S-0509, on the omeprazole-induced proliferation of gastric mucosa in rats.

Authors:  Masahiro Ono; Hiroshi Sato; Hideaki Kazumori; Mika Yuki; Mohammad Azharul Karim Rumi; Cesar Francisco Ortega-Cava; Yasunobu Ishihara; Shunji Ishihara; Kyoichi Adachi; Yoshikazu Kinoshita
Journal:  J Lab Clin Med       Date:  2003-12

8.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

9.  Updated population-based review of carcinoid tumors.

Authors:  Melinda A Maggard; Jessica B O'Connell; Clifford Y Ko
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

  9 in total
  23 in total

1.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

Review 2.  Debulking Surgery for Moderately Differentiated Neuroendocrine Gastric Carcinoma - A Case Report and Literature Review.

Authors:  Nicolae Bacalbasa; Iuliana Halmaciu; Ciprian Bolca; Adrian Neacsu; Dragos Cretoiu; Cristian Balalau; Camelia Diaconu; Laura Iliescu; Alexandru Filipescu; Cora Pop; Irina Balescu
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

3.  Gastric carcinoids: between underestimation and overtreatment.

Authors:  Sara Massironi; Valentina Sciola; Matilde-Pia Spampatti; Maddalena Peracchi; Dario Conte
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

4.  Management of gastric carcinoids (neuroendocrine neoplasms).

Authors:  Mark Kidd; Bjorn I Gustafsson
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 5.  Role of computed tomography angiography in detection and staging of small bowel carcinoid tumors.

Authors:  David Bonekamp; Siva P Raman; Karen M Horton; Elliot K Fishman
Journal:  World J Radiol       Date:  2015-09-28

6.  Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival.

Authors:  Relin Yang; Michael C Cheung; Felipe E Pedroso; Margaret M Byrne; Leonidas G Koniaris; Teresa A Zimmers
Journal:  J Surg Res       Date:  2011-05-23       Impact factor: 2.192

7.  Gender, race, and socioeconomic status affects outcomes after lung cancer resections in the United States.

Authors:  Damien J LaPar; Castigliano M Bhamidipati; David A Harris; Benjamin D Kozower; David R Jones; Irving L Kron; Gorav Ailawadi; Christine L Lau
Journal:  Ann Thorac Surg       Date:  2011-06-25       Impact factor: 4.330

8.  Inhibition of lysosomal enzyme activities by proton pump inhibitors.

Authors:  Wensheng Liu; Susan S Baker; Jonathan Trinidad; Alma L Burlingame; Robert D Baker; John G Forte; Lauren P Virtuoso; Nejat K Egilmez; Lixin Zhu
Journal:  J Gastroenterol       Date:  2013-03-12       Impact factor: 7.527

9.  Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).

Authors:  Dayron Rodríguez; Michael C Cheung; Nadine Housri; Alfredo Quinones-Hinojosa; Kevin Camphausen; Leonidas G Koniaris
Journal:  J Surg Res       Date:  2009-05-14       Impact factor: 2.192

10.  Skeletal Plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database.

Authors:  Muhammad Umar Jawad; Sean P Scully
Journal:  J Hematol Oncol       Date:  2009-09-24       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.